Expert consensus on the clinical application of antibody drug conjugates in the treatment of malignant tumors (2020 Edition) / 中华肿瘤杂志
Chinese Journal of Oncology
;
(12): 78-91, 2021.
Article
Dans Chinois
| WPRIM
| ID: wpr-877499
ABSTRACT
Antibody-drug conjugate (ADC) is a type of targeted biological agent which connect cytotoxic drug to monoclonal antibody by a connector head, which enables monoclonal antibody acted as a carrier to efficiently transport small molecular cytotoxic drugs to target tumor cells. It is very important for clinicians to have an in-depth understanding of the molecular characteristics and mechanism of ADC drugs, rationally choose the appropriate dose, course of treatment and manage adverse reactions according to the indications during the clinical application of ADC drugs, which may even affect the survival of patients. Therefore, the consensus aims to conduct a systematic overview of commercially available ADC drugs, provide effective recommendations and references for clinicians to better apply and manage ADC drugs.
Texte intégral:
Disponible
Indice:
WPRIM (Pacifique occidental)
Sujet Principal:
Immunoconjugués
/
Consensus
/
Anticorps monoclonaux
/
Tumeurs
/
Antinéoplasiques
Type d'étude:
Guide de pratique
/
Revues systématiques évaluées
Limites du sujet:
Humains
langue:
Chinois
Texte intégral:
Chinese Journal of Oncology
Année:
2021
Type:
Article
Documents relatifs à ce sujet
MEDLINE
...
LILACS
LIS